A multicentre, open label, phase I/ randomised Phase II study to evaluate safety, pharmacokinetics, and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients.

Short title	A multicentre, open label, phase I/ randomised Phase II study to evaluate safety, pharmacokinetics, and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients.
Status	Active
Effective start/end date	28/10/09 → 31/12/26

Project Details